Premium
Hematopoietic effects of a granulocyte‐macrophage colony‐stimulating factor/interleukin‐3 fusion protein
Author(s) -
Williams Douglas E.,
Park Linda S.
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910515)67:10+<2705::aid-cncr2820671706>3.0.co;2-m
Subject(s) - haematopoiesis , granulocyte macrophage colony stimulating factor , fusion protein , receptor , granulocyte macrophage colony stimulating factor receptor , colony stimulating factor , interleukin 3 , granulocyte , progenitor cell , cytokine , interleukin , immunology , microbiology and biotechnology , macrophage , medicine , biology , macrophage colony stimulating factor , immune system , t cell , stem cell , biochemistry , recombinant dna , in vitro , gene , antigen presenting cell
The common functional characteristics of granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) and interleukin‐3 (IL‐3) may be explained by the presence of a subpopulation of cell surface receptors capable of binding both growth hormones. A GM‐CSF/IL‐3 fusion protein (pIXY 321) was produced in a yeast expression host. Receptor binding studies with HL‐60, JM‐1, AML‐193, and KG‐1 cell lines suggested that the GM‐CSF and IL‐3 regions had adopted a native conformation within the fusion protein. The fusion protein also exhibited enhanced biologic activity compared with GM‐CSF or IL‐3 in assays of normal, primary human hematopoietic progenitor cells. pIXY 321 may offer significant clinical advantages over the individual cytokines.